Active	Status	Sponsor type	Region	Phase	Filter
6 Active 1 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gleiber, Wolfgang
NCT05874401: Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan	Recruiting	4	302	Europe, RoW	Trilaciclib, G1T28, CDK 4/6 inhibitor, cyclin-dependent kinase 4/6 inhibitor, Placebo, Topotecan, Hycamtin	G1 Therapeutics, Inc.	Extensive-stage Small-cell Lung Cancer	07/27	07/27
NCT04126473 / 2018-000966-12: A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele	Completed	2	17	Europe, RoW	ELX-02, Ivacaftor	Eloxx Pharmaceuticals, Inc., Eloxx Pharmaceuticals Inc	Cystic Fibrosis	04/22	04/22
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology	Completed	N/A	499	Europe		iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG	Advanced Solid Tumors or Hematologic Malignancies	06/23	06/23
CAR-CF, NCT05012306: Covid-19 Antibody Responses in Cystic Fibrosis	Active, not recruiting	N/A	500	Europe		Universitätsklinikum Köln	Cystic Fibrosis	05/24	05/24
Endres, Kristina
CAR-CF, NCT05012306: Covid-19 Antibody Responses in Cystic Fibrosis	Active, not recruiting	N/A	500	Europe		Universitätsklinikum Köln	Cystic Fibrosis	05/24	05/24
Eickmeier, Olaf
CAR-CF, NCT05012306: Covid-19 Antibody Responses in Cystic Fibrosis	Active, not recruiting	N/A	500	Europe		Universitätsklinikum Köln	Cystic Fibrosis	05/24	05/24